We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Misonix Sells Sonablate 500 Console and Sonatherm 600 to US HIFU

By HospiMedica International staff writers
Posted on 07 Jun 2010
Misonix Inc. (MSON; Farmingdale, NY, USA), a leading developer, manufacturer, and marketer of ultrasonic surgical devices, has agreed to sell its "Focus Surgery” related assets plus its European distribution rights to US HIFU LLC (Charlotte, N.C., USA), a privately held healthcare company focused on treating primary and recurrent prostate cancer using HIFU, for US$5.8 million.

The transaction entitles US HIFU with rights to acquire Sonatherm 600, a laparoscopic HIFU system used in the ablation of certain soft tissues. Furthermore, US HIFU will hold distribution rights for Misonix's SB500 console, with Misonix retaining intellectual property rights to the three HIFU patents, which were acquired from ProRhythm in June 2009.

The agreement allows Misonix to focus on minimizing additional operating costs and in developing its own proprietary medical devices such as the HIFU transducers and lens technology. Misonix's President and CEO, Michael A. McManus, Jr. commented on the deal "Going forward, we will be a dedicated ultrasonic surgical device company developing, manufacturing and selling only devices we own outright."

The acquisition of the Sonatherm 600 is a major step for US HIFU; this being the company's first significant device, which has received the mandatory US Food and Drug Administration (FDA; Atlanta, GA, USA), clearance, for commercialization in the United States. Sonatherm is a high intensity focused ultrasound (HIFU) treatment of soft tissue, developed by Misonix after it acquired worldwide rights for the product from Focus Surgery, Inc. in July 2008.

The addition of Sonablate HIFU (a minimally invasive medical device used for the treatment of prostate cancer) will add momentum to the US HIFU's plans for a Pan European initiative to showcase the enhanced efficacy of Sonablate HIFU. This device, which is authorized and commercially available in more than 30 other countries, is in its final phase of the FDA's clinical trials.

"This transaction brings Sonablate manufacturing, and research and development together again under one roof… allowing for increased efficiency operationally and an expansion of our HIFU product portfolio," said US HIFU's CEO Steve Puckett, Jr.

Related Links:

Misonix Inc.
US HIFU




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Medical-Grade POC Terminal
POC-821
New
Cannulating Sphincterotome
TRUEtome

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024